Exiqon A/S
Innovative assay systems for use in high through-put applications in pharmacogenetics, functional genomics and proteomics
Exiqon was founded in 1996 and is located in the Medicon Valley area of Copenhagen, Denmark. The company was ISO certified in January 2006.
Lars Kongsbak (CEO)
Jack Johansen (Chairman)
Michael Nobel
Henrik Lawaetz
Markku Fagerlund
Steinar J. Engelsen
Bygstubben 9
2950 Vedbaek
Denmark
Phone: +45-45-66-08-88
Fax: +45-45-66-18-88
Exiqon is the global provider of Locked Nucleic Acid (LNA™) and supplier of gene expression analysis products (miRCURY™).
The company’s miRCURY™ array capture probes consists of a Tm-normalised microarray set for all human, mouse and rat miRNAs as registered and annotated in the miRBase at The Wellcome Trust Sanger Institute.
Related news
- Roche and Exiqon Agree on Joint Marketing Approach for their RT PCR Assay Systems
- Exiqon to present at 28th J.P. Morgan Healthcare Conference
- Exiqon to divest its U.S. CLIA laboratory operation Oncotech, Inc.
- Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award.
- Exiqon Expands in US; Sales Headquarters Established
- Exiqon Announces New Global Distribution Points
